菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

Global Top 1%: WuXi Biologics Included in S&P Global’s Sustainability Yearbook 2024 (China Edition)
Aug. 06, 2024
Global Top 1%: WuXi Biologics Included in S&P Global’s Sustainability Yearbook 2024 (China Edition)

Shanghai, August 6, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in S&P Global’s Sustainability Yearbook 2024 (China Edition)–with a Global Top 1% S&P Global Corporate Sustainability Assessment (CSA) ranking–and named as an Industry Mover. The recognitions were announced at the recent S&P Global Sustainable1 Sustainability Seminar in Beijing.S&P Global’s Sustainability Yearbook is the only analysis of its kind based on its annual CSA evaluation, and it serves as a benchmarking resource for corporate sustainability performance. More than 1,700 companies assessed in the 2023 CSA were considered for inclusion in the Yearbook 2024 (China Edition). S&P Global identified the top performing companies in each industry, and from those selected 129 with the best performance for listing in the Yearbook.

 

Earlier this year, WuXi Biologics was included into the global Sustainability Yearbook, with the Global Top 1% score and the recognition of Industry Mover in its global ranking.

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to be included in the S&P Global Yearbook, following our inclusion in the DJSI World Index and Emerging Markets Index last year. These achievements are a reflection of and recognition for our continuous commitment to enhancing ESG capabilities and further advancing the company’s sustainability performance for the common good of the global community.”

 

In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development. In the past year, the company signed the Science Based Targets initiative (SBTi) commitment letter and became a signatory to the United Nations Global Compact, demonstrating its sustainability commitment.

 

The company’s efforts have been recognized by major ESG rating agencies. It was granted an “AAA” rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis. Earlier this year, the company was named to MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score; and named a Constituent of the FTSE4Good Index Series.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

ESG
esg@wuxibiologics.com

 

Media
PR@wuxibiologics.com